Alzheimer's and Dementia: The Journal of the Alzheimer's Association This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial
DiscussionS-CitAD will provide information about a practical, immediately available approach to treating agitation in patients with AD. S-CitAD may become a model of how to evaluate and predict treatment response in patients with AD and agitation as a neuropsychiatric symptom (ClinicalTrials.gov Identifier: NCT03108846). (Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association)
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - October 4, 2019 Category: Geriatrics Source Type: research

Perspective: Clinical relevance of the dichotomous classification of Alzheimer's disease biomarkers: Should there be a “gray zone”?
Publication date: Available online 26 September 2019Source: Alzheimer's & DementiaAuthor(s): Kevin McRae-McKee, Chinedu T. Udeh-Momoh, Geraint Price, Sumali Bajaj, Celeste A. de Jager, David Scott, Christoforos Hadjichrysanthou, Emily McNaughton, Luc Bracoud, Sara Ahmadi-Abhari, Frank de Wolf, Roy M. Anderson, Lefkos T. Middleton, Alzheimer's Disease Neuroimaging InitiativeAbstractThe 2018 National Institute on Aging and the Alzheimer's Association (NIA-AA) research framework recently redefined Alzheimer's disease (AD) as a biological construct, based on in vivo biomarkers reflecting key neuropathologic features. Combinat...
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - September 27, 2019 Category: Geriatrics Source Type: research

Apolipoprotein E ε4 allele effects on longitudinal cognitive trajectories are sex and age dependent
DiscussionResults highlight the importance of considering sex and age when assessing APOE-ε4–associated vulnerability to cognitive decline. (Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association)
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - September 25, 2019 Category: Geriatrics Source Type: research

Differences in service utilization at an urban tribal health organization before and after Alzheimer's disease or related dementia diagnosis: A cohort study
DiscussionThis is the only study quantifying changes in healthcare service utilization before and after ADRD diagnosis among ANAI people, which is crucial for tailoring geriatric care for ANAI populations. (Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association)
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - September 25, 2019 Category: Geriatrics Source Type: research

Multidomain intervention and/or omega-3 in nondemented elderly subjects according to amyloid status
DiscussionMI alone or in combination with omega-3 fatty acids was associated with improved primary cognitive outcome in subjects with positive amyloid status.Trial RegistrationClinicalTrials.gov Identifier: NCT01513252. (Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association)
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - September 25, 2019 Category: Geriatrics Source Type: research

Do Alzheimer's and Lewy body disease have discrete pathological signatures of gait?
Publication date: Available online 20 September 2019Source: Alzheimer's & DementiaAuthor(s): Ríona Mc Ardle, Brook Galna, Paul Donaghy, Alan Thomas, Lynn RochesterAbstractObjectiveWe aimed to refine the hypothesis that dementia has a unique signature of gait impairment reflective of underlying pathology by considering two dementia subtypes, Alzheimer's disease (AD) and Lewy body disease (LBD), and exploring the role of cognition in disease-specific gait impairments.BackgroundAccurately differentiating AD and LBD is important for treatment and disease management. Early evidence suggests gait could be a marker of dementia d...
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - September 20, 2019 Category: Geriatrics Source Type: research

Paul Greengard, Ph.D. (1925-2019)
Publication date: September 2019Source: Alzheimer's & Dementia, Volume 15, Issue 9Author(s): Sam Gandy, Toshiharu Suzuki (Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association)
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - September 19, 2019 Category: Geriatrics Source Type: research

Epilepsy and Alzheimer's disease: Overlapping mechanisms and therapeutic opportunities
Publication date: September 2019Source: Alzheimer's & Dementia, Volume 15, Issue 9Author(s): Alzheimer's (Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association)
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - September 19, 2019 Category: Geriatrics Source Type: research

Contents
Publication date: September 2019Source: Alzheimer's & Dementia, Volume 15, Issue 9Author(s): (Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association)
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - September 19, 2019 Category: Geriatrics Source Type: research

Editorial Board
Publication date: September 2019Source: Alzheimer's & Dementia, Volume 15, Issue 9Author(s): (Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association)
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - September 19, 2019 Category: Geriatrics Source Type: research

Medical and Scientific Advisory Council
Publication date: September 2019Source: Alzheimer's & Dementia, Volume 15, Issue 9Author(s): (Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association)
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - September 19, 2019 Category: Geriatrics Source Type: research

Subscriber Information
Publication date: September 2019Source: Alzheimer's & Dementia, Volume 15, Issue 9Author(s): (Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association)
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - September 19, 2019 Category: Geriatrics Source Type: research

Quantitative gait, cognitive decline, and incident dementia: The Rotterdam Study
DiscussionPoor performance on several independent gait domains precedes cognitive decline and incident dementia. (Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association)
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - September 11, 2019 Category: Geriatrics Source Type: research

The Alzheimer's Disease Exposome
DiscussionWe propose the “AD exposome” to comprehensively assess the modifiable environmental factors relevant to genetic underpinnings of cognitive aging and AD. Analysis of endogenous and exogenous environmental factors requires multi-generational consideration of these interactions over age and time (GxExT). New computational approaches to the multi-level complexities may identify accessible interventions for individual brain aging. International collaborations on diverse populations are needed to identify the most relevant exposures over the life course for GxE interactions. (Source: Alzheimer's and Dementia: The J...
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - September 11, 2019 Category: Geriatrics Source Type: research

A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials
DiscussionThe harmonized database is an optimum resource to design AD prevention trials decades before symptomatic onset. (Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association)
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - September 8, 2019 Category: Geriatrics Source Type: research